Market & Regulation
GSK and Relation Therapeutics in $110M AI Drug Discovery Deal
AI Newshigh confidence
Why it matters
- →The collaboration emphasizes the integration of biological data with AI for drug discovery.
- →Specialized datasets are becoming crucial for developing robust AI models in biopharma.
- →The partnership reflects a growing trend of AI-driven approaches in pharmaceutical research.
GSK has partnered with Relation Therapeutics in a research collaboration valued at up to $110 million, focusing on AI-assisted drug discovery. Relation will generate extensive datasets on human cellular responses to genetic changes and drug interventions, which will be used to train AI models for drug target identification. This agreement highlights the importance of biological data in AI model development, building on previous collaborations between the two companies. The partnership reflects a broader industry trend towards specialized datasets in biopharma, essential for advancing AI applications in drug discovery.
Read originalMore from AI News
Researchresearch
Stanford's Evo 2 AI Model Creates E. coli Phages
Stanford's Evo 2 AI model has made a significant leap in synthetic biology by generating phages that effectively target E. coli. This breakthrough demonstrates the potential of AI to design entire viral genomes, moving beyond simple DNA edits. The model produced thousands of candidate genomes, with 16 showing strong E. coli-killing activity in lab tests. By releasing Evo 2 as open-source software, Stanford is inviting further exploration and innovation in genome design, potentially paving the way for new treatments against resistant bacteria like MRSA.
AI News
Market & Regulationbusiness
Alibaba explores revenue-sharing for Qwen AI model
Alibaba is testing a new business model for its upcoming Qwen open-weight AI model, introducing revenue-sharing terms for commercial users. This move targets larger companies that profit from offering the model as a service, requiring them to enter a commercial agreement with Alibaba. The approach mirrors the licensing model used by Moonshot for its Kimi K3 model, which includes revenue-sharing for companies exceeding certain revenue thresholds. This shift signifies Alibaba's strategy to monetize its open-weight models while maintaining their open-source nature, potentially setting a precedent for other AI developers.
